Bryan Johnson argues high-dose psychedelics like psilocybin are a longevity therapy, not just mental health medicine, because they reset metabolic and neural aging pathways.
In a quantified experiment, Johnson found a high 25-milligram dose of psilocybin lowered his blood glucose from the 99.5th to the 99.9th percentile, a shift he says is more dramatic than what metformin achieves.
The key longevity benefit Johnson observes is a durable, childlike neuroplastic state post-experience, evidenced by a quieted internal monologue and simple, non-defensive conflict resolution.
Johnson's quantified approach aims to reframe the psychedelic experience from spiritual anecdote to a measurable biomarker reset of the aging clock.
Beyond your filters
Nathaniel Whittemore says this IPO race will force both Anthropic and OpenAI to prioritize profitable enterprise tools over experimental features.
Beyond your filtersStartupsEnterprisevia The AI Daily Brief: Artificial Intelligence News and AnalysisThe Global Uncertainty Index recently hit 105,000, a record high surpassing levels seen during 9/11 and the 2008 financial crisis.
Britain’s core interest in Persia was maintaining cheap oil for the Royal Navy, not preserving Persian sovereignty.
Today's edition is light (4 results)